<p>Adverum Biotechnologies, Inc.（纳斯达克代码：ADVM - 获取免费报告）首席执行官 Laurent Fischer 于 12 月 5 日星期五购买了 11,085 股 Adverum Biotechnologies 股票。该股票的平均购买成本为每股 4.24 美元，总交易额为 47,000.40 美元。购买后，首席执行官直接持有该公司 83,899 股股票，估值约为 355,731.76 美元。此次交易使其持股增加了 15.22%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
<p>Laurent Fischer 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 8 日星期一，Laurent Fischer 购买了 117,614 股 Adverum Biotechnologies 股票。该股票的平均购买成本为每股 4.31 美元，总价值为 506,916.34 美元。</li>
</ul>
<h2>Adverum Biotechnologies 价格表现</h2>
<p>在周一的交易中，Adverum Biotechnologies 股票上涨了 0.10 美元，达到 4.36 美元。该公司交易了 987,543 股，相比其平均交易量 447,123 股。该公司的 50 日移动平均价格为 4.41 美元，200 日移动平均价格为 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低价为 1.78 美元，最高价为 6.12 美元。该公司的市值为 9626 万美元，市盈率为-0.51，贝塔值为 0.87。</p>
<p>Adverum Biotechnologies（纳斯达克代码：ADVM - 获取免费报告）最近一次发布财报是在 11 月 12 日星期三。这家生物技术公司报告了本季度每股收益（EPS）为-2.03 美元，低于市场共识预期的-1.80 美元，差距为 0.23 美元。整体来看，股票研究分析师预计 Adverum Biotechnologies, Inc.在当前年度的每股收益将为-4.92 美元。</p>
<h2>机构投资者对 Adverum Biotechnologies 的看法</h2>
<p>几家机构投资者最近买入和卖出了 ADVM 的股票。Y Intercept Hong Kong Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值约为 45,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度购买了 Adverum Biotechnologies 的新股份，价值 58,000 美元。XTX Topco Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值 64,000 美元。Qube Research &amp; Technologies Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值 66,000 美元。最后，Marshall Wace LLP 在第二季度购买了价值 107,000 美元的 Adverum Biotechnologies 新股份。机构投资者持有该公司 48.17% 的股票。</p>
<h2>分析师评级调整</h2>
<p>几家券商最近对 ADVM 发表了评论。HC Wainwright 在 11 月 17 日星期一的研究报告中重申了 “中性” 评级，并将 Adverum Biotechnologies 的目标价设定为 5.00 美元（之前为 30.00 美元）。Chardan Capital 在 10 月 27 日星期一的研究报告中将 Adverum Biotechnologies 的评级从 “强力买入” 下调至 “持有”。Mizuho 在 10 月 29 日星期三的研究报告中将 Adverum Biotechnologies 的目标价设定为 5.50 美元。加拿大皇家银行在 10 月 28 日星期二的研究报告中将 Adverum Biotechnologies 的目标价设定为 4.00 美元。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Adverum Biotechnologies 的 “卖出（d-）” 评级。一位研究分析师对该股票给予了买入评级，四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 10.50 美元。</p>
<p><strong>查看我们关于 Adverum Biotechnologies 的最新研究报告</strong></p>
<h2>关于 Adverum Biotechnologies</h2>
<p>（获取免费报告）</p>
<p>Adverum Biotechnologies, Inc.是一家临床阶段公司，开发基因治疗产品候选药物以治疗眼科疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的单次玻璃体内注射基因治疗候选药物，目前正在进行第二阶段临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Adverum Biotechnologies</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Adverum Biotechnologies 吗？</h2>
<p>在你考虑 Adverum Biotechnologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Adverum Biotechnologies 并不在名单上。</p>
<p>虽然 Adverum Biotechnologies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Adverum生物科技

<p>Adverum 生物科技首席执行官 Laurent Fischer 购买了 11,085 股，增持幅度为 15.22%。此次购买价格为每股 4.24 美元，总计 47,000.40 美元。Fischer 目前持有 83,899 股，市值为 355,731.76 美元。该交易已在 SEC 备案中披露。Adverum 的股票交易价格为 4.36 美元，市值为 9626 万美元。分析师的评级意见不一，普遍共识为 “持有”，目标价格为 10.50 美元。该公司开发用于眼科疾病的基因治疗，其主要候选药物正在进行第二阶段临床试验</p>

<p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer bought 11,085 shares of Adverum Biotechnologies stock in a transaction dated Friday, December 5th. The stock was acquired at an average cost of $4.24 per share, for a total transaction of $47,000.40. Following the purchase, the chief executive officer directly owned 83,899 shares in the company, valued at approximately $355,731.76. The trade was a 15.22% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.（纳斯达克代码：ADVM - 获取免费报告）首席执行官 Laurent Fischer 于 12 月 5 日星期五购买了 11,085 股 Adverum Biotechnologies 股票。该股票的平均购买成本为每股 4.24 美元，总交易额为 47,000.40 美元。购买后，首席执行官直接持有该公司 83,899 股股票，估值约为 355,731.76 美元。此次交易使其持股增加了 15.22%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
</div><p>Laurent Fischer also recently made the following trade(s):</p>
<div class="lb-trans"><p>Laurent Fischer 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, December 8th, Laurent Fischer acquired 117,614 shares of Adverum Biotechnologies stock. The shares were bought at an average cost of $4.31 per share, with a total value of $506,916.34.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 8 日星期一，Laurent Fischer 购买了 117,614 股 Adverum Biotechnologies 股票。该股票的平均购买成本为每股 4.31 美元，总价值为 506,916.34 美元。</li>
</ul>
</div><h2>Adverum Biotechnologies Price Performance</h2>
<div class="lb-trans"><h2>Adverum Biotechnologies 价格表现</h2>
</div><p>Shares of Adverum Biotechnologies stock traded up $0.10 during trading on Monday, hitting $4.36. 987,543 shares of the company were exchanged, compared to its average volume of 447,123. The firm's fifty day moving average price is $4.41 and its 200 day moving average price is $3.35. Adverum Biotechnologies, Inc. has a 1-year low of $1.78 and a 1-year high of $6.12. The firm has a market capitalization of $96.26 million, a P/E ratio of -0.51 and a beta of 0.87.</p>
<div class="lb-trans"><p>在周一的交易中，Adverum Biotechnologies 股票上涨了 0.10 美元，达到 4.36 美元。该公司交易了 987,543 股，相比其平均交易量 447,123 股。该公司的 50 日移动平均价格为 4.41 美元，200 日移动平均价格为 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低价为 1.78 美元，最高价为 6.12 美元。该公司的市值为 9626 万美元，市盈率为-0.51，贝塔值为 0.87。</p>
</div><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.80) by ($0.23). As a group, equities research analysts anticipate that Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>Adverum Biotechnologies（纳斯达克代码：ADVM - 获取免费报告）最近一次发布财报是在 11 月 12 日星期三。这家生物技术公司报告了本季度每股收益（EPS）为-2.03 美元，低于市场共识预期的-1.80 美元，差距为 0.23 美元。整体来看，股票研究分析师预计 Adverum Biotechnologies, Inc.在当前年度的每股收益将为-4.92 美元。</p>
</div><h2>Institutional Investors Weigh In On Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>机构投资者对 Adverum Biotechnologies 的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of ADVM. Y Intercept Hong Kong Ltd acquired a new position in Adverum Biotechnologies during the 2nd quarter worth approximately $45,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Adverum Biotechnologies in the third quarter worth $58,000. XTX Topco Ltd acquired a new position in Adverum Biotechnologies during the second quarter worth $64,000. Qube Research &amp; Technologies Ltd acquired a new position in Adverum Biotechnologies during the second quarter worth $66,000. Finally, Marshall Wace LLP bought a new position in Adverum Biotechnologies in the second quarter valued at $107,000. Institutional investors own 48.17% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了 ADVM 的股票。Y Intercept Hong Kong Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值约为 45,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度购买了 Adverum Biotechnologies 的新股份，价值 58,000 美元。XTX Topco Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值 64,000 美元。Qube Research &amp; Technologies Ltd 在第二季度新建了 Adverum Biotechnologies 的持仓，价值 66,000 美元。最后，Marshall Wace LLP 在第二季度购买了价值 107,000 美元的 Adverum Biotechnologies 新股份。机构投资者持有该公司 48.17% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several brokerages recently commented on ADVM. HC Wainwright reaffirmed a &#34;neutral&#34; rating and set a $5.00 price objective (down previously from $30.00) on shares of Adverum Biotechnologies in a research note on Monday, November 17th. Chardan Capital lowered Adverum Biotechnologies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, October 27th. Mizuho set a $5.50 price objective on Adverum Biotechnologies in a research report on Wednesday, October 29th. Royal Bank Of Canada set a $4.00 target price on Adverum Biotechnologies in a research note on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Adverum Biotechnologies in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $10.50.</p>
<div class="lb-trans"><p>几家券商最近对 ADVM 发表了评论。HC Wainwright 在 11 月 17 日星期一的研究报告中重申了 “中性” 评级，并将 Adverum Biotechnologies 的目标价设定为 5.00 美元（之前为 30.00 美元）。Chardan Capital 在 10 月 27 日星期一的研究报告中将 Adverum Biotechnologies 的评级从 “强力买入” 下调至 “持有”。Mizuho 在 10 月 29 日星期三的研究报告中将 Adverum Biotechnologies 的目标价设定为 5.50 美元。加拿大皇家银行在 10 月 28 日星期二的研究报告中将 Adverum Biotechnologies 的目标价设定为 4.00 美元。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Adverum Biotechnologies 的 “卖出（d-）” 评级。一位研究分析师对该股票给予了买入评级，四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 10.50 美元。</p>
</div><p><strong>View Our Latest Research Report on Adverum Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Adverum Biotechnologies 的最新研究报告</strong></p>
</div><h2>About Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>关于 Adverum Biotechnologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.是一家临床阶段公司，开发基因治疗产品候选药物以治疗眼科疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的单次玻璃体内注射基因治疗候选药物，目前正在进行第二阶段临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Adverum Biotechnologies</li>
<li>3 Stocks to Consider Buying in October</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Adverum Biotechnologies</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADVM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adverum Biotechnologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Adverum Biotechnologies 吗？</h2>
</div><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adverum Biotechnologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Adverum Biotechnologies 并不在名单上。</p>
</div><p>While Adverum Biotechnologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adverum Biotechnologies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Adverum 生物科技（NASDAQ:ADVM）的首席执行官购买了价值 47,000.40 美元的股票